Met Life Investment Management, LLC Sage Therapeutics, Inc. Transaction History
Met Life Investment Management, LLC
- $18 Billion
- Q4 2024
A detailed history of Met Life Investment Management, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 25,636 shares of SAGE stock, worth $186,373. This represents 0.0% of its overall portfolio holdings.
Number of Shares
25,636
Previous 30,712
16.53%
Holding current value
$186,373
Previous $221,000
37.1%
% of portfolio
0.0%
Previous 0.0%
Shares
33 transactions
Others Institutions Holding SAGE
# of Institutions
194Shares Held
45MCall Options Held
304KPut Options Held
117K-
Black Rock Inc. New York, NY5.22MShares$37.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.84MShares$35.2 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.59MShares$33.4 Million0.0% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.46MShares$32.4 Million0.48% of portfolio
-
Rtw Investments, LP New York, NY3MShares$21.8 Million0.27% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $432M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...